Hepatitis C inhibitor peptides
US6767991B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 5, 1999 |
| Grant date | Jul 27, 2004 |
| Priority date | — |
| Expiry date | Aug 5, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/24222
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are hepatitis C viral protease inhibitors of formula (I): wherein a is 0 or 1; b is 0 or 1; Y is H or C1-6 alkyl;B is H, an acyl derivative or a sulfonyl derivative;R6, when present, is C1-6 alkyl substituted with carboxyl;R5, when present, is C1-6 alkyl optionally substituted with carboxyl;R4 is C1-10 alkyl, C3-7 cycloalkyl or C4-10 (alkylcycloalkyl);R3 is C1-10 alkyl optionally substituted with carboxyl, C3-7 cycloalkyl or C4-10 (alkylcycloalkyl);R2 is CH2—R20, NH—R20, O—R20 or S—R20; wherein R20 is a saturated or unsaturated C3-7 cycloalkyl or C4-10 (alkyl cycloalkyl) being optionally mono-, di- or tri-substituted withR21, or R20 is a C6 or C10aryl, C7-16 aralkyl, Het or (lower alkyl)-Het, all optionally mono-, di- or tri-substituted with R21, wherein R21 is as defined herein;R1 is C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, all optionally substituted with halogen; andW is hydroxy or a N-substituted amino: or W taken together with the carbonyl group to which it is bonded represents an ester group, or a pharmaceutically acceptable salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.